Skip to main content

As part of these interactions, Pharming provided the FDA with the results of two completed Phase 2 trials of RUCONEST® for the prophylaxis of HAE attacks; a randomized, double-blind, placebo-controlled trial and an open-label study. The two studies enrolled a total of 56 patients and showed consistent efficacy and safety results.

“We look forward to continuing to work with the FDA to expand treatment options with RUCONEST® for HAE patients.”

- Dr. Bruno Giannetti, Pharming’s COO
Cookies: This website uses cookies Check the cookies page for more information Accept Decline